| Bioactivity | KRCA-0713 is an ALK inhibitor with anti-ALK activity. KRCA-0713 showed promising anti-ALK activity in enzyme and cell-based experiments. KRCA-0713 was shown to effectively inhibit ALK-driven tumor growth in H3122 xenograft model studies, similar to the effect of ceritinib[1]. |
| CAS | 1884321-89-4 |
| Formula | C26H32ClN5O3S |
| Molar Mass | 530.08 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor |
KRCA-0713
CAS: 1884321-89-4 F: C26H32ClN5O3S W: 530.08
KRCA-0713 is an ALK inhibitor with anti-ALK activity. KRCA-0713 showed promising anti-ALK activity in enzyme and cell-ba
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.